Bio-Thera Collaborates with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) Across the US
Shots:
- Bio-Thera and Intas Pharmaceuticals have entered into an exclusive commercialization and license agreement for BAT2506, a biosimilar version of Simponi (golimumab) in the US
- As per the agreement, Bio-Thera is entitled to receive $21M upfront and an additional $143.5M in development and commercial milestones
- BAT2506 is an IgG1 monoclonal antibody targeting TNF-alpha, reducing inflammatory markers like CRP, IL-6, ICAM-1, MMP-3, and VEGF. The reference medicine is approved in US and Europe for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis
Ref: Prnewswire | Image: Bio-Thera & Intas Pharmaceuticals
Related News:- Bio-Thera Reports the EMA’s MAA Acceptance of BAT2506 (Biosimilar, Simponi)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
